A treasure trove of new leads on drug targets and biomarkers has been uncovered in a huge proteomics study
A massive research collaboration between 13 pharmaceutical companies and the UK Biobank has uncovered a trove of new leads for drug targets and diagnostic biomarkers, revealing thousands of previously unknown associations with common genetic variants and proteins circulating in the blood.
The work, known as the Pharma Proteomics Project, has the potential to start unveiling the causes of many common conditions. It builds on two decades of work on the role of genetics in disease, pairing existing genetic data with new analyses of about 2,900 blood proteins from 54,000 people.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.